Observational studyAnnals of clinical and translational neurology2025
Observational Study of Tocilizumab in Children With Febrile Infection-Related Epilepsy Syndrome.
Observational study in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploring pathways leading to drug-resistant epilepsy for patients with cryptogenic new onset refractory status epilepticus.Epilepsia · 2026Article
- Blockade of Interleukin-6 Receptor with Tocilizumab During the Acute Phase of Childhood Immune-Mediated Epilepsy can Lead to a Favorable Outcome - an Observational Study.Current neuropharmacology · 2026Observational
- The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to assess the efficacy and safety of using tocilizumab in children with febrile infection-related epilepsy syndrome (FIRES) and explore tocilizumab-related changes in interleukin (IL)-6 levels.
methodsPatients with FIRES admitted to the Intensive Care Unit (ICU) of Beijing Children's Hospital were retrospectively included and categorized into tocilizumab and control groups based on whether tocilizumab was administered to compare prognostic differences and drug safety. Patients in the tocilizumab group were further classified into response (characterized by ≥ 50% reduction in seizure frequency on electroencephalogram within one-week post-treatment) and no-response groups for intergroup comparison of tocilizumab regimens and clinical outcomes. Serum and CSF IL-6 levels were collected before and after the first tocilizumab dose to analyze the dynamics.
resultsOf 58 enrolled patients with FIRES, 23 received tocilizumab. The tocilizumab group showed higher rates of consciousness recovery and favorable Pediatric Cerebral Performance Category scores (p < 0.05). The incidence of post-FIRES epilepsy was lower in the tocilizumab group (p < 0.001). The response group (9 patients) received earlier tocilizumab treatment, had shorter mechanical ventilation and ICU durations, and experienced higher consciousness recovery rates (p < 0.05). Serum IL-6 levels increased post-treatment (p = 0.003), while CSF IL-6 levels showed a non-significant decline (p = 0.080). There was no significant difference in the rates of combined infection, liver function impairment, and total cholesterol elevation between the tocilizumab and control groups (p > 0.05).
interpretationEarly tocilizumab administration may improve outcomes in patients with FIRES, with a clinically acceptable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.